We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Finds Data Deficiencies in Provention Bio’s Diabetes Drug Submission
FDA Finds Data Deficiencies in Provention Bio’s Diabetes Drug Submission
The FDA has found deficiencies in the biologics license application (BLA) data submitted for Provention Bio’s teplizumab, a monoclonal antibody being reviewed for delaying or preventing type 1 diabetes, and the agency’s evaluation of it is likely to be delayed as a result, the company said.